Li, Jian
Deng, Yanhong
Zhang, Weijie
Zhou, Ai-Ping
Guo, Weijian
Yang, Jianwei
Yuan, Ying
Zhu, Liangjun
Qin, Shukui
Xiang, Silong
Lu, Haolan
Gong, John
Xu, Ting
Liu, David
Shen, Lin
Funding for this research was provided by:
3D Medicines Co., Ltd, China
Article History
Received: 18 May 2021
Accepted: 21 May 2021
First Online: 21 June 2021
Declarations
:
: The study was approved at each site by the local independent ethics committee. All enrolled patients provided signed, informed consent for participation.
: Not applicable.
: SX, HL, JG, and DL are employees of and own stock in 3D Medicines Co., Ltd. JG and DL have leadership roles at 3D Medicines Co., Ltd. LS has received research funding from 3D Medicines Co., Ltd. XT is an employee of Alphamab Co., Ltd, where he has a leadership role and owns stock. The other authors declare no conflicts of interest.